医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

MiracleIN Agrees with Ajou University to Jointly Develop Medicine for Preventing Various Viruses and Bacteria, Including MERS, Ebola and SARS

2015年07月31日 PM09:00
このエントリーをはてなブックマークに追加


 

INCHEON, South Korea

MiracleIN, a Korean venture company that developed electrolytic technology for eco-friendly water treatment, announced that it signed on July 31, an agreement with Ajou University College of Pharmacy for jointly developing medicine for preventing infectious diseases caused by various viruses and bacteria.

The project will be led by Prof. Lee Joo-yeoun and Prof. Kim Su-dong at Ajou University College of Pharmacy based on MiracleIN’s composition under development.

When this new drug is developed, Ajou University’s College of Pharmacy will register it with Korea’s Ministry of Food, Drug and Safety, and then seek to register with the U.S. FDA after developing technologies in conjunction with University of Maryland in the United States.

A scientist at Ajou University College of Pharmacy said, “As the substance under development is known to be effective for spatial sterilization and sterilization of various facilities at medical institutions, it will be helpful for protecting health and safety of the people in case infectious diseases, such as novel swine-origin influenza and Middle East respiratory syndrome (MERS), occur.”

Meanwhile, MiracleIN is currently developing eco-friendly water treatment technology in collaboration with Smart Convergence Technology Research Center (Prof. Lee Joo-yeoun) at Ajou University, and they will apply it to hospitals, power plants and ballast water. Scientists have already completed test of the technology for pools. With strong sterilizing power, the technology is an eco-friendly sterilizing system that has neither smell of bleacher nor poison. It also causes no secondary pollution of environment when it is emitted.

In addition, MiracleIN has concluded an MOU with POSCO ICT for jointly developing next generation water treatment technology.

Based on its subsidiary in Dallas, Texas, MiracleIN is seeking to expand into global market of pools and treatment of underground water estimated to reach KRW20 trillion a year.

For more information about MiracleIN, visit http://www.miracleingroup.com/kr/ .

View source version on businesswire.com: http://www.businesswire.com/news/home/20150731005180/en/

CONTACT

MiracleIN
Eun Yeong Bak, 82-32-837-5555
info@miracleingroup.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 印尼生命科学与技术学院在NCRM NICHE 2021上赢得第16届Fujio Cup Quiz大赛;印度Rajalakshmi工程学院获得亚军
  • 辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析
  • ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
  • 硕迪B轮成功融资1亿美元,利用先进的计算和结构药物设计平台加速开发改变患者命运的药物
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease